KRTAP1-3

gene

On this page

Also known as KAP1.3

Summary

KRTAP1-3 (keratin associated protein 1-3, HGNC:16771) is a protein-coding gene on chromosome 17q21.2, encoding Keratin-associated protein 1-3 (Q8IUG1). In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-link….

This protein is a member of the keratin-associated protein (KAP) family. The KAP proteins form a matrix of keratin intermediate filaments which contribute to the structure of hair fibers. KAP family members appear to have unique, family-specific amino- and carboxyl-terminal regions and are subdivided into three multi-gene families according to amino acid composition: the high sulfur, the ultrahigh sulfur, and the high tyrosine/glycine KAPs. This protein is a member of the high sulfur KAP family and the gene is localized to a cluster of KAPs at 17q12-q21.

Source: NCBI Gene 81850 — RefSeq curated summary.

At a glance

Clinical variants (ClinVar): 37 total
MANE Select transcript: NM_030966

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16771
Approved symbol	KRTAP1-3
Name	keratin associated protein 1-3
Location	17q21.2
Locus type	gene with protein product
Status	Approved
Aliases	KAP1.3
Ensembl gene	ENSG00000221880
Ensembl biotype	protein_coding
OMIM	608820
Entrez	81850

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000344363

RefSeq mRNA: 1 — MANE Select: NM_030966 NM_030966

CCDS: CCDS42323

Canonical transcript exons

ENST00000344363 — 1 exons

Exon	Start	End
ENSE00001475004	41033884	41034874

Expression profiles

Bgee: expression breadth broad, 46 present calls, max score 47.20.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0510 / max 38.5049, expressed in 5 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
165866	0.0510	5

Top tissues by expression

110 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skin of abdomen	UBERON:0001416	47.20	gold quality
zone of skin	UBERON:0000014	44.95	gold quality
skin of leg	UBERON:0001511	43.57	gold quality
right lung	UBERON:0002167	41.04	gold quality
colonic epithelium	UBERON:0000397	37.20	gold quality
ventricular zone	UBERON:0003053	36.48	gold quality
cortical plate	UBERON:0005343	36.47	gold quality
bone marrow cell	CL:0002092	36.16	gold quality
ganglionic eminence	UBERON:0004023	35.49	gold quality
skeletal muscle tissue	UBERON:0001134	35.11	gold quality
muscle tissue	UBERON:0002385	32.33	gold quality
hindlimb stylopod muscle	UBERON:0004252	32.15	gold quality
bone marrow	UBERON:0002371	31.74	gold quality
gastrocnemius	UBERON:0001388	31.26	gold quality
muscle of leg	UBERON:0001383	31.16	gold quality
sural nerve	UBERON:0015488	30.93	gold quality
blood	UBERON:0000178	30.66	gold quality
stromal cell of endometrium	CL:0002255	29.87	gold quality
cortex of kidney	UBERON:0001225	29.71	gold quality
prefrontal cortex	UBERON:0000451	29.57	gold quality
duodenum	UBERON:0002114	28.14	gold quality
kidney	UBERON:0002113	28.07	gold quality
monocyte	CL:0000576	27.90	gold quality
leukocyte	CL:0000738	27.87	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	27.59	gold quality
lymph node	UBERON:0000029	27.57	gold quality
heart left ventricle	UBERON:0002084	27.53	silver quality
popliteal artery	UBERON:0002250	27.46	gold quality
tibial artery	UBERON:0007610	27.44	gold quality
adult mammalian kidney	UBERON:0000082	27.22	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

41 targeting KRTAP1-3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-3912-5P	99.95	66.11	925
HSA-MIR-767-5P	99.95	70.85	993
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-302A-3P	99.89	71.23	1777
HSA-MIR-302B-3P	99.89	71.23	1777
HSA-MIR-302C-3P	99.89	71.20	1778
HSA-MIR-302D-3P	99.89	71.25	1777
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-373-3P	99.84	70.68	1668
HSA-MIR-520E-3P	99.84	70.55	1698
HSA-MIR-372-3P	99.83	70.58	1691
HSA-MIR-520A-3P	99.83	70.59	1687
HSA-MIR-520B-3P	99.83	70.56	1699
HSA-MIR-520C-3P	99.83	70.56	1699
HSA-MIR-520D-3P	99.83	70.78	1676
HSA-MIR-520F-3P	99.82	71.32	1216
HSA-MIR-636	99.80	69.58	1500
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-498-5P	99.76	69.64	1807
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-488-3P	99.61	68.79	1731
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-12117	99.50	67.57	868
HSA-MIR-6128	99.33	67.83	1581
HSA-MIR-10522-5P	99.26	68.50	2087
HSA-MIR-6770-5P	98.97	66.76	1853
HSA-MIR-3926	98.95	69.26	1438

Literature-anchored findings (GeneRIF, showing 1)

polymorphisms in Japanese and Caucasian individuals (PMID:12228244)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Krtap1-5	ENSMUSG00000047253
rattus_norvegicus	Krtap1-5	ENSRNOG00000084854

Paralogs (47): KRTAP4-4 (ENSG00000171396), KRTAP9-7 (ENSG00000180386), KRTAP5-5 (ENSG00000185940), KRTAP12-1 (ENSG00000187175), KRTAP9-8 (ENSG00000187272), KRTAP10-8 (ENSG00000187766), KRTAP10-6 (ENSG00000188155), KRTAP1-1 (ENSG00000188581), KRTAP10-12 (ENSG00000189169), KRTAP4-3 (ENSG00000196156), KRTAP9-9 (ENSG00000198083), KRTAP4-6 (ENSG00000198090), KRTAP4-5 (ENSG00000198271), KRTAP4-1 (ENSG00000198443), KRTAP9-3 (ENSG00000204873), KRTAP4-8 (ENSG00000204880), KRTAP1-4 (ENSG00000204887), KRTAP12-3 (ENSG00000205439), KRTAP10-2 (ENSG00000205445), KRTAP5-6 (ENSG00000205864), KRTAP5-2 (ENSG00000205867), KRTAP16-1 (ENSG00000212657), KRTAP9-6 (ENSG00000212659), KRTAP4-11 (ENSG00000212721), KRTAP4-9 (ENSG00000212722), KRTAP2-3 (ENSG00000212724), KRTAP2-1 (ENSG00000212725), KRTAP10-3 (ENSG00000212935), KRTAP4-12 (ENSG00000213416), KRTAP2-4 (ENSG00000213417), KRTAP2-2 (ENSG00000214518), KRTAP10-4 (ENSG00000215454), KRTAP10-1 (ENSG00000215455), KRTAP10-9 (ENSG00000221837), KRTAP1-5 (ENSG00000221852), KRTAP10-10 (ENSG00000221859), KRTAP12-2 (ENSG00000221864), KRTAP9-2 (ENSG00000239886), KRTAP9-1 (ENSG00000240542), KRTAP4-7 (ENSG00000240871)

Protein

Protein identifiers

Keratin-associated protein 1-3 — Q8IUG1 (reviewed: Q8IUG1)

Alternative names: Keratin-associated protein 1.8, Keratin-associated protein 1.9

All UniProt accessions (1): Q8IUG1

UniProt curated annotations — full annotation on UniProt →

Function. In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins.

Subunit / interactions. Interacts with hair keratins.

Tissue specificity. Expressed in the middle/upper portions of the hair cortex, in the region termed the keratogenous zone.

Polymorphism. The sequence shown is that of allele KAP1.3.

Similarity. Belongs to the KRTAP type 1 family.

RefSeq proteins (1): NP_112228* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002494	KAP	Family

Pfam: PF01500

UniProt features (5 total): sequence variant 4, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IUG1-F1	42.11	0.00

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-6805567	Keratinization
R-HSA-1266738	Developmental Biology

MSigDB gene sets: 44 (showing top): GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_DN, MARTINEZ_RB1_TARGETS_DN, GOCC_INTERMEDIATE_FILAMENT_CYTOSKELETON, GOCC_KERATIN_FILAMENT, GOMF_STRUCTURAL_MOLECULE_ACTIVITY, GOCC_SUPRAMOLECULAR_COMPLEX, GOCC_POLYMERIC_CYTOSKELETAL_FIBER, GOMF_STRUCTURAL_CONSTITUENT_OF_SKIN_EPIDERMIS, REACTOME_KERATINIZATION, GOCC_SUPRAMOLECULAR_POLYMER, LHX9_TARGET_GENES, PHB2_TARGET_GENES, SRSF9_TARGET_GENES, ZNF512_TARGET_GENES, ZNF512B_TARGET_GENES

GO Biological Process (0):

GO Molecular Function (2): structural constituent of skin epidermis (GO:0030280), protein binding (GO:0005515)

GO Cellular Component (3): cytosol (GO:0005829), keratin filament (GO:0045095), intermediate filament (GO:0005882)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
structural molecule activity	1
binding	1
cytoplasm	1
cellular anatomical structure	1
intermediate filament	1
intermediate filament cytoskeleton	1
polymeric cytoskeletal fiber	1

Protein interactions and networks

STRING

342 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KRTAP1-3	EMP1	P54849	641
KRTAP1-3	KRTAP3-2	Q9BYR7	507
KRTAP1-3	KRTAP22-1	Q3MIV0	506
KRTAP1-3	KRTAP24-1	Q3LI83	478
KRTAP1-3	KRTAP6-1	Q3LI64	474
KRTAP1-3	KRTAP6-2	Q3LI66	474
KRTAP1-3	KRTAP13-3	Q3SY46	450
KRTAP1-3	CD5	P06127	447
KRTAP1-3	KRTAP27-1	Q3LI81	436
KRTAP1-3	KRTAP7-1	Q8IUC3	421
KRTAP1-3	MAGEA11	P43364	405
KRTAP1-3	SERPINA1	P01009	396
KRTAP1-3	KRTAP15-1	Q3LI76	384
KRTAP1-3	C1D	Q13901	375
KRTAP1-3	CD19	P15391	370

IntAct

551 interactions, top by confidence:

A	B	Type	Score
CYSRT1	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.740
PRKAB2	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.700
TNS2	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.700
OTX1	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.700
GLRX3	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.490
GRAP2	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.490
KRTAP1-3	GRAP2	psi-mi:“MI:0915”(physical association)	0.490
UTP23	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.000
HCK	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.000
TGFB1	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.000
JOSD1	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.000
	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.000
R3HDM2	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.000
SLC22A23	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.000
NID2	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.000
ZNF696	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.000
GSTP1	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.000
PVR	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.000
XCL2	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.000
PRPF31	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.000
SLC43A2	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.000
SHFL	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.000
PTK7	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.000
GLP1R	KRTAP1-3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (187): KRTAP1-3 (Two-hybrid), KRTAP1-3 (Two-hybrid), KRTAP1-3 (Two-hybrid), KRTAP1-3 (Two-hybrid), KRTAP1-3 (Two-hybrid), KRTAP1-3 (Two-hybrid), KRTAP1-3 (Two-hybrid), KRTAP1-3 (Two-hybrid), KRTAP1-3 (Two-hybrid), KRTAP1-3 (Two-hybrid), KRTAP1-3 (Two-hybrid), KRTAP1-3 (Two-hybrid), KRTAP1-3 (Two-hybrid), KRTAP1-3 (Two-hybrid), KRTAP1-3 (Two-hybrid)

ESM2 similar proteins: A0A286YEV6, A0A286YEX9, A0A286YEY9, A0A286YF01, A0A286YF46, A0A286YF60, A0A286YF77, A0A286YFB4, A0A286YFG1, O14633, P02438, P04459, P05687, P05688, P08131, P08175, P0DSO2, P20730, Q01642, Q01643, Q01644, Q01645, Q07627, Q3LI58, Q3LI59, Q3V2C1, Q5T750, Q5T752, Q5T754, Q5TA78, Q5TA79, Q5TA81, Q5TA82, Q5TCM9, Q8IUC1, Q8IUG1, Q9BQ66, Q9BYP8, Q9BYQ5, Q9BYQ6

Diamond homologs: P02438, P02439, P02440, P08131, P0C5Y4, Q07627, Q3V2C1, Q8IUG1, Q9BYS1

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 119 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Keratinization	20	13.6×	4e-15
Formation of the cornified envelope	11	11.8×	3e-07

GO biological processes:

GO term	Partners	Fold	FDR
keratinization	11	24.5×	5e-10

Disease & clinical

Clinical variants and AI predictions

ClinVar

37 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	30
Likely benign	5
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

245 predictions. Top by Δscore:

Variant	Effect	Δscore
17:41034140:CTTT:C	acceptor_gain	0.9000
17:41034141:TTT:T	acceptor_gain	0.8700
17:41034121:T:TG	acceptor_loss	0.8100
17:41034150:T:TC	acceptor_gain	0.8100
17:41034311:CTGG:C	donor_gain	0.8100
17:41034144:C:CC	acceptor_gain	0.7900
17:41034146:G:C	acceptor_loss	0.7900
17:41034236:T:TA	donor_gain	0.7700
17:41034193:CCCCA:C	acceptor_gain	0.7600
17:41034498:C:CT	donor_gain	0.7600
17:41034150:T:C	acceptor_gain	0.7500
17:41034196:C:CT	acceptor_gain	0.7500
17:41034499:C:CT	donor_gain	0.7500
17:41034142:TT:T	acceptor_gain	0.7400
17:41034121:TC:T	acceptor_gain	0.7300
17:41034310:A:AC	donor_gain	0.7300
17:41034311:C:CC	donor_gain	0.7300
17:41034314:G:A	donor_gain	0.7000
17:41034194:C:CA	donor_gain	0.6700
17:41034276:C:CC	acceptor_gain	0.6700
17:41034230:T:TA	donor_gain	0.6500
17:41034556:C:CT	donor_gain	0.6400
17:41034620:T:TA	donor_gain	0.6200
17:41034122:C:A	acceptor_gain	0.6100
17:41034321:G:C	donor_gain	0.6100
17:41034141:T:C	acceptor_gain	0.5900
17:41034149:A:AC	acceptor_gain	0.5900
17:41034118:T:TA	donor_gain	0.5800
17:41034271:TGGAA:T	acceptor_gain	0.5800
17:41034196:C:T	acceptor_gain	0.5700

AlphaMissense

1105 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1001987944 (17:41033751 C>T), RS1002559645 (17:41035928 G>A), RS1002634710 (17:41034498 C>T), RS1006277125 (17:41035797 T>C), RS1007026035 (17:41036876 C>A,T), RS1008263749 (17:41036401 C>A,T), RS1008658861 (17:41033865 A>G), RS1008795419 (17:41035143 T>G), RS1008849080 (17:41035332 G>T), RS1009197715 (17:41033640 C>A), RS1010792911 (17:41033799 G>T), RS1011671080 (17:41036589 C>G), RS1012890086 (17:41035031 A>G), RS1013432773 (17:41033567 T>C), RS1014679336 (17:41035463 G>A)

Disease associations

OMIM: gene MIM:608820 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): autism spectrum disorder (MONDO:0005258)

Orphanet (1): NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

9 total (human), top 9 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects expression, decreases expression, increases methylation	3
sodium arsenite	increases stability	1
Cadmium	decreases expression, increases abundance	1
Estradiol	affects expression	1
Tetrachlorodibenzodioxin	increases expression	1
Valproic Acid	decreases methylation	1
Aflatoxin B1	decreases methylation	1
Cadmium Chloride	decreases expression, increases abundance	1
Copper Sulfate	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	PHASE3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
NCT04725383	PHASE3	TERMINATED	Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT05212493	PHASE3	COMPLETED	The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05439616	PHASE3	COMPLETED	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
NCT06229210	PHASE3	RECRUITING	Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.